Faced with the dual challenges of increasing economic downturn pressure and weakened profitability, the pharmaceutical industry in Jiangxi Province continues to maintain rapid development. According to the announcement released by the Provincial Commission of Economy and Information Technology, in 2015, the pharmaceutical industry above designated size in Hubei Province broke the 100 billion mark for the first time.

In 2015, Jiangxi Province achieved a main business revenue of 106.6 billion yuan, a year-on-year increase of 10.3%, ranking 9th in total. Fixed assets investment of the province's pharmaceutical industry reached 42.098 billion yuan, up 16.2% year on year. 4.3 percentage points higher than the national average.

Active pharmaceutical innovation and outstanding technological achievements. Last year, the province obtained a total of 11 drug registration approvals, including 5 new drug approvals. A batch of large varieties have been cultivated, with 24 varieties having a single product sales revenue of over 100 million yuan, 9 varieties having a single product sales revenue of over 200 million yuan, and 5 varieties having a single product sales revenue of over 300 million yuan.

The restructuring and integration are accelerating, and the industrial layout is becoming more coordinated. Last year, the number and scale of corporate mergers and acquisitions increased, integrating industry resources and enhancing the core competitiveness of enterprises. There is one pharmaceutical industry in the province with a main revenue exceeding 10 billion yuan, one with over 5 billion yuan, and four with over 2 billion yuan. It is expected that by the end of the 13th Five Year Plan period, the pharmaceutical industry in the province is expected to achieve a sales revenue of 220 billion yuan, doubling compared to the 12th Five Year Plan period.

It is reported that there are currently 17 industries with a total of 100 million yuan.